Clinical Trial Update: Open-Label Safety Study of ADS-5102 in PD Patients With LID [Phase 3]

View source ↗

Summary

Open-label safety study of ADS-5102 in Parkinson's disease patients with levodopa-induced dyskinesia completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Levodopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• ADS-5102 (amantadine)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Dyskinesia, Levodopa Induced Dyskinesia (LID) | Phase 3 | Status: COMPLETED | Results posted: 2020-09-16